Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 μg | 5 days | $ 184.00 | |
50 μg | 5 days | $ 545.00 | |
500 μg | 5 days | $ 2,070.00 | |
1 mg | 5 days | $ 2,970.00 |
Description | Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer. |
Species | Human |
Expression System | Human Cells |
Tag | C-6His |
Accession Number | P20151 |
Synonyms | hGK-1, Kallikrein-2, Tissue Kallikrein-2, KLK2, Glandular Kallikrein-1 |
Amino Acid | Pro19-Pro261 |
Construction | Recombinant Human Kallikrein 2 is produced by our Mammalian expression system and the target gene encoding Pro19-Pro261 is expressed with a 6His tag at the C-terminus. |
Protein Purity | Greater than 95% as determined by reducing SDS-PAGE. Greater than 95% as determined by SEC-HPLC. |
Molecular Weight | (10-12)&(16-19)&(28-33) KDa, reducing conditions |
Endotoxin | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
Formulation | Supplied as a 0.2 μm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02% Tween 80, pH5.0. |
Stability & Storage |
Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Shipping |
The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below. |
Research Background | Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
Kallikrein 2/KLK2 Protein, Human, Recombinant (His) KLK 2 hGK-1 Kallikrein-2 Tissue Kallikrein-2 KLK-2 KLK2 Glandular Kallikrein-1 recombinant recombinant-proteins proteins protein